Novartis AG (NYSE:NVS) ranks third among the most undervalued pharma stocks to buy now. The Swiss pharmaceutical leader focuses on innovative treatments in various disease areas and invests heavily in R&D. Kisqali, a treatment for metastatic breast cancer, saw a 64% global sales increase in Q2 2025. Other therapies like Pluvicto and Scemblix show promising momentum.

Novartis AG (NYSE:NVS) is expanding into nephrology with FDA approvals for Vanrafia and Fabhalta. The company introduced Coartem Baby, a pediatric malaria treatment for infants under 5 kg. Novartis plans to launch it on a not-for-profit basis in malaria-endemic regions. The corporation’s pipeline includes Phase III trials for autoimmune diseases, lupus, and neuroimmunological disorders.

Novartis AG’s Kisqali has emerged as a blockbuster drug with record Q2 growth, positioning it for success. The company has a focused pipeline with promising Phase III trials ongoing. While NVS offers investment potential, some AI stocks may provide greater upside. Explore opportunities in the AI sector for potential growth and benefits.

Read more at Yahoo Finance: Kisqali Emerges as Novartis AG (NVS) Blockbuster with Record Q2 Growth